Efficacy and safety of BRAF-MEK inhibitors in treatment of Chinese patients with papillary craniopharyngioma: A retrospective cohort study

Previous research supports the efficacy of BRAF-MEK inhibitor therapy for papillary craniopharyngiomas (PCPs). This retrospective study of 30 Chinese PCP patients evaluated tumor response and safety outcomes during treatment. All patients maintained 100% progression-free and overall survival through...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Rui Han, Xiaorong Yan, Boyuan Yao, Boyu Cai, Nidan Qiao, Zengyi Ma, Zhen Ye, Xufang Gu, Zhao Ye, Buqing Liang, Zhengyuan Chen, Wenqiang He, Yifei Yu, Xiaoyun Cao, Haixia Cheng, Hong Chen, Yongfei Wang, Hongying Ye, Zhaoyun Zhang, Yao Zhao, Ruofan Huang, Qilin Zhang
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2025-12-01
Rangatū:	Molecular Therapy: Oncology
Ngā marau:	MT: Regular Issue papillary craniopharyngiomas PCPs BRAF-MEK inhibitors nature history efficacy
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S2950329925001547
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!